GlassScriptPhysician profile
Artin Minaeian
NPI 1013356344
$171,883.79
in general payments reported to CMS, 2019-2025
92 companies · $56K in 2025
The $56K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $7,455 · 2021: $20K · 2022: $18K · 2023: $15K · 2024: $45K · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Food and Beverage: $17K · Consulting Fee: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,840 · Travel and Lodging: $2,380 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $77,421.25 |
| Food and Beverage | $17,023.59 |
| Consulting Fee | $10,830.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,840.00 |
| Travel and Lodging | $2,379.86 |
| Education | $197.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $48,822.08 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Abbvie INC. | $44,842.93 | 2020-2025 | |
| Eisai INC. | $17,858.10 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $15,931.70 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Tg Therapeutics, INC. | $10,743.07 | 2023-2025 | |
| Emd Serono, INC. | $4,173.66 | 2019-2025 | Mavenclad, Mavenclad |
| Biohaven Pharmaceutical Holding Company LTD. | $4,057.91 | 2022 | |
| Medtronic Vascular, INC. | $2,145.17 | 2019-2020 | |
| Allergan, INC. | $1,676.46 | 2019-2022 | |
| Ucb, INC. | $1,628.65 | 2019-2025 | Nayzilam, Rystiggo, Briviact |
| Biogen, INC. | $1,568.72 | 2019-2025 | Vumerity, Tysabri |
| Celgene Corporation | $1,408.03 | 2021-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $1,367.27 | 2019-2025 | |
| Amgen INC. | $1,025.27 | 2019-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $995.53 | 2019-2025 | Ultomiris, Soliris |
Show all 87 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $952.39 | 2021-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $919.39 | 2020-2025 | Xcopri |
| Acadia Pharmaceuticals INC | $714.45 | 2019-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $608.02 | 2021-2025 | Rytary, Crexont |
| Pfizer INC. | $589.26 | 2019-2025 | |
| Medtronic, INC. | $510.51 | 2021-2022 | |
| Neurelis, INC. | $502.15 | 2022-2025 | Valtoco |
| Astrazeneca Pharmaceuticals LP | $462.26 | 2021-2024 | Andexxa, Wainua |
| Argenx US, INC. | $457.09 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Mdd US Operations, LLC | $433.43 | 2019-2024 | Gocovri, Apokyn |
| Neurocrine Biosciences, INC. | $410.15 | 2020-2024 | Ingrezza, Ongentys |
| Livanova USA, INC. | $380.57 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Horizon Therapeutics Plc | $377.76 | 2021-2023 | Uplizna |
| Genentech USA, INC. | $373.02 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Janssen Pharmaceuticals, INC | $358.08 | 2020-2023 | Ponvory |
| Genzyme Corporation | $326.05 | 2019-2025 | |
| Imperative Care, INC | $310.32 | 2023-2024 | Zoom 88-T Large Distal Platform |
| Otsuka America Pharmaceutical, INC. | $310.06 | 2023-2025 | Nuedexta, Rexulti |
| Boston Scientific Corporation | $307.26 | 2019-2025 | Watchman, General - Dbs |
| Acorda Therapeutics, INC | $288.66 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $242.98 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $184.67 | 2019-2024 | Amvuttra |
| Mallinckrodt Hospital Products INC. | $170.77 | 2024 | Acthar |
| Abbott Laboratories | $167.38 | 2019-2023 | Infinity |
| Avanir Pharmaceuticals, INC. | $167.32 | 2019-2021 | |
| Stryker Corporation | $165.41 | 2022-2023 | Trevo |
| Corium, LLC | $163.30 | 2022-2023 | Adlarity |
| Upsher-Smith Laboratories LLC | $160.86 | 2019-2022 | |
| Kyowa Kirin, INC. | $154.22 | 2020-2023 | Nourianz |
| Adamas Pharmaceuticals, INC. | $141.46 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $129.75 | 2025 | Ponvory |
| Viz.Ai, INC. | $124.60 | 2021 | |
| Sunovion Pharmaceuticals INC. | $122.61 | 2019-2022 | |
| Cycle Pharmaceuticals INC | $122.06 | 2025 | Tascenso Odt, Bafiertam |
| Biohaven Pharmaceuticals, INC. | $116.24 | 2021 | |
| Ani Pharmaceuticals, INC. | $115.72 | 2024-2025 | Purified Cortrophin Gel |
| Merz Pharmaceuticals, LLC | $111.75 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Janssen Scientific Affairs, LLC | $105.73 | 2019 | |
| Ge Healthcare | $91.17 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.61 | 2020-2023 | Gammagard |
| Sumitomo Pharma America, INC. | $81.60 | 2023-2024 | Aptiom |
| Arbor Pharmaceuticals, INC. | $80.33 | 2020-2021 | |
| Akcea Therapeutics, INC. | $70.53 | 2019-2021 | |
| Genentech, INC. | $68.40 | 2023 | Ocrevus, Enspryng |
| Octapharma USA, INC. | $67.88 | 2023 | Panzyga |
| Catalyst Pharmaceuticals, INC. | $57.34 | 2023 | Fycompa |
| Vertical Pharmaceuticals, LLC | $56.29 | 2019 | |
| Csl Behring | $52.81 | 2021-2025 | Hizentra |
| Galderma Laboratories, L.P. | $50.68 | 2019 | |
| Tanabe Pharma America, INC. | $42.80 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $38.40 | 2020-2021 | |
| Microtransponder, INC. | $38.39 | 2022-2023 | |
| Depuy Synthes Sales INC. | $33.10 | 2020 | |
| Jazz Pharmaceuticals INC. | $32.96 | 2024 | |
| Avid Radiopharmaceuticals, INC. | $32.50 | 2024 | |
| Vertiflex, INC. | $32.23 | 2019 | |
| Aucta Pharmaceuticals, INC. | $30.52 | 2024-2025 | Motpoly Xr |
| Janssen Biotech, INC. | $28.39 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $28.20 | 2025 | |
| Route 92 Medical, INC. | $27.35 | 2025 | |
| Axsome Therapeutics, INC. | $26.49 | 2025 | Symbravo |
| Greenwich Biosciences, INC. | $26.28 | 2020 | |
| Portola Pharmaceuticals, LLC | $25.70 | 2019 | |
| Microvention, INC. | $24.84 | 2020 | |
| Medtronic USA, INC. | $23.63 | 2020 | |
| Harmony Biosciences LLC | $23.19 | 2022 | |
| Cala Health, INC. | $21.79 | 2023 | Cala Kiq, Cala Trio |
| Novo Nordisk INC | $20.40 | 2019 | |
| Banner Life Sciences, LLC | $18.04 | 2023 | |
| Amylyx Pharmaceuticals, INC. | $15.13 | 2023 | Relyvrio |
| Idorsia Pharmaceuticals US INC | $13.84 | 2022 | |
| Currax Pharmaceuticals LLC | $11.72 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$42,562.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Artin Minaeian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.